This product is an ASHP Learning Center activity.

Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Target Audience

These activities are designed for pharmacists who are interested in expanding their knowledge and skills in specialty pharmacy management of advanced pulmonary disease states.

Overview

The Specialty Pharmacy Certificate is self-guided, with online learning activities allowing learners to tailor their learning experience.

A learner will have completed the Specialty Pharmacy Fundamentals before beginning the Advanced Pulmonary Disease States Track.

The learner will then take a deep dive into their selected specialty focus with the Advanced Pulmonary Disease States Track. These topics include pulmonary structure and inhaled products overview, severe asthma, chronic pulmonary obstructive disease (COPD) management, interstitial lung disease (ILD), and pulmonary hypertension (PH).

Professional Certificate Requirement

Once a learner has completed the Specialty Pharmacy Fundamentals and the Advanced Pulmonary Disease States track educational curriculum, they will have the opportunity to complete the track final exam. Once the learner successfully completes the track final exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.

Educational Activities

Pulmonary Structure and Inhaled Products Overview
ACPE: 0204-0000-24-727-H01-P
Knowledge-based
2 contact hours

Learning Objectives:

• Identify the role and function of key components of the pulmonary system.
• Describe factors that influence the deposition of inhaled medications in the airways.
• Discuss strategies that optimize delivery of medications to the lungs.

Severe Asthma and COPD
ACPE: 0204-0000-24-728-H01-P
Application-based
1.25 contact hours

Learning Objectives:

• Differentiate between difficult-to-treat and severe asthma.
• Compare predictors of response across asthma biologics to aid in therapy choice for severe asthma treatment.
• Design a therapy monitoring plan to assess the safety and efficacy of a given asthma biologic.
• Identify characteristics that would suggest a patient is a candidate for alpha-1 antitrypsin deficiency testing.
• Develop key counseling points and considerations for patients starting treatment for alpha-1 antitrypsin deficiency.

Interstitial Lung Disease (ILD)
ACPE: 0204-0000-24-729-H01-P
Application-based
2.5 contact hours

Learning Objectives:

• Differentiate diagnostic criteria for the major subtypes of Interstitial Lung Disease (ILD).
• Select appropriate patient monitoring for an ILD subtype.
• Evaluate the role of corticosteroids in the acute management of ILD.
• Assess the immunosuppressant (steroidal or nonsteroidal/steroid-sparing) therapeutic options for the treatment of ILD.
• Evaluate the biologic therapeutic options for the treatment of ILD.
• Assess the role of antifibrotic options for the treatment of ILD.
• Identify adverse effects by therapeutic drug class for treatment of ILD.
• Explain the barriers for ILD treatment options, including limited distribution, cost, and patient-specific factors.
• Given a patient case, design a therapeutic plan for the treatment for a major subtypes of ILD, including monitoring for efficacy and safety.
• Given a patient case, recommend alternatives for treatment-related side effects in a patient on a specific therapeutic option.

Pulmonary Hypertension (PH)
ACPE: 0204-0000-24-730-H01-P
Application-based
4 contact hours

Learning Objectives:

• Use right heart catheterization and hemodynamic values to identify the clinical classifications of pulmonary hypertension.
• Choose appropriate treatment strategies for patients with groups 2-5 pulmonary hypertension.
• Identify the WHO functional class for PAH patients based on self-reported symptoms and limitations.
• Evaluate patient-specific risk factors to quantify disease severity in patients with PAH. 
• Interpret a vasodilatory test for use in the treatment management of PAH patients.
• Identify the primary treatment targets in PAH and the drug classes within each pathway.
• Compare treatment options for high-risk PAH patients.
• Modify treatment plans based on patient-specific parameters (drug-drug interactions, side effects, renal function, etc.)
• Choose a treatment regimen for a newly diagnosed PAH patient based on patient-specific risk factors used to quantify disease severity.
• Design an appropriate monitoring plan for patients initiated on pulmonary vasodilator therapy.
• Identify strategies to address barriers associated with transitioning PAH therapies between care settings.
• Identify barriers to initiation of PAH-targeted therapies in the acute care setting.

Faculty Information

Heidi Brink, PharmD, BCPS, BCCP
Associate Professor
Clinical Pharmacy Supervisor - Cardiology & Cardiothoracic Transplant
Omaha, Nebraska

Megan Fleischman, PharmD, BCACP
Assistant Professor of Pharmacy Practice
Concordia University Wisconsin - School of Pharmacy
Mequon, Wisconsin

Specialist Pharmacist
Froedtert Health
Menomonee Falls, Wisconsin

Amber Lanae Martirosov, PharmD, BCPS, BCACP
Associate Clinical Professor
Wayne State University

Clinical Pharmacy Specialist – Ambulatory Care
Henry Ford Health
Detroit, Michigan

Dennis Williams, PharmD, BCPS, AE-C, FASHP, FAPHA, FCCP
Associate Professor
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Relevant Financial Relationship Disclosure

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company.

Methods and CE Requirements

Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP profile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.

ASHP PROFESSIONAL CERTIFICATES^SM contain learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.

System Technical Requirements

System requirements courses and learning activities are delivered via your web browser and Acrobat PDF. Users should have a basic comfort level using a computer and navigating web sites. View the minimum technical and system requirements for learning activities.